Title: A novel phosphocholine-mimetic inhibits a pro-inflammatory conformational change in C-reactive protein
Authors: Zeller, J
Shing, KSCT
Nero, TL
McFadyen, JD
Krippner, G
Bogner, B
Kreuzaler, S
Kiefer, J
Horner, VK
Braig, D
Danish, H
Baratchi, S
Fricke, M
Wang, XW
Kather, MG
Kammerer, B
Woollard, KJ
Sharma, P
Morton, CJ
Pietersz, G
Parker, MW
Peter, K
Eisenhardt, SU
Issue Year: 2023
Publisher WILEY
Series EMBO MOLECULAR MEDICINE:
Abstract C-reactive protein (CRP) is an early-stage acute phase protein and highly upregulated in response to inflammatory reactions. We recently identified a novel mechanism that leads to a conformational change from the native, functionally relatively inert, pentameric CRP (pCRP) structure to a pentameric CRP intermediate (pCRP*) and ultimately to the monomeric CRP (mCRP) form, both exhibiting highly pro-inflammatory effects. This transition in the inflammatory profile of CRP is mediated by binding of pCRP to activated/damaged cell membranes via exposed phosphocholine lipid head groups. We designed a tool compound as a low molecular weight CRP inhibitor using the structure of phosphocholine as a template. X-ray crystallography revealed specific binding to the phosphocholine binding pockets of pCRP. We provide in vitro and in vivo proof-of-concept data demonstrating that the low molecular weight tool compound inhibits CRP-driven exacerbation of local inflammatory responses, while potentially preserving pathogen-defense functions of CRP. The inhibition of the conformational change generating pro-inflammatory CRP isoforms via phosphocholine-mimicking compounds represents a promising, potentially broadly applicable anti-inflammatory therapy.
URI: https://publications.svi.edu.au/publications/8679
Other Identifiers 10.15252/emmm.202216236
Publication type Article